CONFLICTLIVE
Global Disease Outbreak

US Flu Season Winding Down After a Deadly Run for Children

The 2025-26 US flu season is declining but has claimed 139 child lives, with 85% of deaths in unvaccinated children.

Child receiving flu vaccine from healthcare worker

Overview

The 2025–26 influenza season in the United States is showing clear signs of decline, but public health officials are offering no celebrations. As transmission rates fall across most of the country and emergency department visits trend downward, the human cost of the season — particularly among the youngest patients — continues to mount. The season has now claimed the lives of 139 children, with a further 12 pediatric deaths reported in the most recent surveillance week, according to data tracked by the Centers for Disease Control and Prevention (CDC) and reported by the Center for Infectious Disease Research and Policy (CIDRAP).

Influenza remains one of the most reliably underestimated infectious diseases in the public imagination. Unlike novel pathogens that generate sustained media coverage, seasonal flu cycles through populations with enough familiarity that its lethality is often discounted — especially in wealthy nations with access to effective vaccines. This season’s pediatric toll is a pointed reminder that familiarity does not equal safety.

Current Situation

flu hospital pediatric ward Image: Wikimedia Commons

The headline figure from the latest CDC surveillance data is stark: 139 children have died from influenza complications during the 2025–26 season to date. The addition of 12 more deaths in a single reporting week — even as overall transmission indicators decline — signals that the virus retains its capacity to kill even as community spread winds down. Pediatric influenza deaths in the United States are individually reported to the CDC, making this count among the more reliable mortality metrics in domestic influenza surveillance.

Of the children who died and whose vaccination status was documented, approximately 85% were unvaccinated at the time of infection. This figure, cited by CIDRAP, is consistent with patterns observed in prior seasons and carries significant epidemiological weight: it suggests that vaccination, while imperfect, continues to offer meaningful protection against the most severe outcomes, including death.

Seasonal flu mortality data in the United States is reported with a lag, and total burden — including adult deaths — is estimated rather than directly counted at the population level. The CDC uses statistical modeling to estimate overall influenza-associated mortality, which in moderate-to-severe seasons can reach tens of thousands. Pediatric deaths, however, are subject to mandatory individual reporting, giving analysts a cleaner signal on that specific demographic.

Affected Regions

The 2025–26 season followed a broadly national spread pattern typical of influenza A-dominated years. Influenza A viruses, which tend to drive more severe seasons than influenza B, circulate across all 50 states during peak transmission periods, with no region fully spared. The southeastern and south-central United States historically report earlier and more intense activity, a pattern that again appeared to hold this season before the wave moved northward.

By the time of the most recent reporting period, CIDRAP noted that activity was declining broadly, suggesting the season is past its peak nationally. However, late-season transmission pockets remain possible, particularly in communities with lower vaccination coverage or concentrated vulnerable populations. Flu seasons in the Northern Hemisphere typically run from October through May, meaning weeks of residual activity likely remain even as the trend line falls.

The geographic distribution of pediatric deaths has not been broken down by state in publicly available summary data at this reporting stage. However, deaths tend to correlate broadly with population size, prior immunity gaps, and local vaccination rates — metrics that vary considerably across regions.

Risk Assessment

CDC influenza surveillance data Image: Wikimedia Commons

Influenza’s risk profile is often misread in public discourse. It is not a single static threat but a family of rapidly evolving viruses whose severity shifts year to year depending on the dominant strain, population immunity, and vaccine match. The 2025–26 season appears to have been moderately to severely burdensome, at least for pediatric populations, based on the fatality data available.

The unvaccinated remain the highest-risk group for severe pediatric outcomes. The 85% unvaccinated rate among child deaths points to a population of children who either lacked access to vaccination, whose caregivers declined it, or who were missed by routine immunization touchpoints. Children under age 5 — and particularly those under 2 — face disproportionate risk from influenza complications, as do children with underlying conditions such as asthma, neurological disorders, and immunocompromising conditions.

Beyond the pediatric population, influenza poses serious risks to adults over 65, pregnant individuals, and those with chronic cardiovascular or pulmonary disease. The CDC’s Advisory Committee on Immunization Practices (ACIP) recommends annual influenza vaccination for virtually all individuals aged 6 months and older, with few medical contraindications.

It is worth noting that the current season’s mortality data does not yet reflect final tallies. As death certificates are processed and surveillance systems catch up with reporting lag, the total pediatric death count for 2025–26 will likely increase before the season is officially closed.

With 85% of child flu deaths occurring in unvaccinated children this season, pediatric influenza vaccination remains the single most effective intervention for preventing these deaths.

Prevention & Response

Annual influenza vaccination continues to be the primary public health tool for reducing flu-associated morbidity and mortality. In the United States, the CDC and ACIP recommend vaccination for everyone six months of age and older, with particular emphasis on high-risk groups. Vaccines are typically reformulated each year to match the strains expected to circulate based on Southern Hemisphere surveillance data and World Health Organization (WHO) guidance.

The effectiveness of flu vaccines varies by season — typically ranging from roughly 40% to 60% in preventing medically attended illness in the general population — but evidence consistently shows that vaccination reduces the risk of severe outcomes, hospitalization, and death across age groups. The 85% unvaccinated share of this season’s child deaths aligns with data from previous years and reinforces the case for closing pediatric vaccination gaps.

Antiviral medications, particularly oseltamivir (Tamiflu), remain an important secondary line of defense. When administered within 48 hours of symptom onset, antivirals can reduce the duration and severity of illness and are especially recommended for high-risk patients. Access and timely administration remain practical challenges, particularly in underserved communities or when patients delay seeking care.

At the public health system level, the CDC’s influenza surveillance network provides weekly updates throughout the season, tracking outpatient visits, emergency department trends, hospitalizations, and deaths. This infrastructure allows health officials to monitor the season’s trajectory and adjust messaging accordingly. As the 2025–26 season recedes, public health authorities will begin analyzing its data to inform vaccine strain selection and preparedness planning for the 2026–27 cycle.

For the remainder of this season, health officials continue to recommend that any unvaccinated individuals — particularly children and older adults — consult their healthcare provider about late-season vaccination, as flu activity, though declining, has not yet ceased. Caregivers of young children and individuals in high-risk categories are encouraged to remain attentive to early symptoms and seek timely medical evaluation.

Sources

Sources